Recent Press Releases

Therapeutic Solutions International Reports NanoStilbene™ Protects the Immune System from Cancer Chemotherapy

Feng Lin, MD, Ph.D., Joins Therapeutic Solutions International as Chief Scientific Officer

Therapeutic Solutions International Announces Positive Clinical Data Using NanoStilbene™ to Stimulate Immune System in Advanced Cancer Patients

Therapeutic Solutions International Collaborates with Right to Try Foundation on Novel Means of Protecting Patients While Hyper-accelerating Drug Development

NanoStilbene™ Nutraceutical Shown to Increase Ability of Cyclophosphamide Chemotherapy to Suppress Cancer

Therapeutic Solutions International Reports its NanoStilbene™ Nutraceutical Product Enhances Efficacy of FDA Cleared Cancer Immunotherapy in Animal Model of Cancer

Therapeutic Solutions International adds Nano Cannabidiol to NanoMyros for Inhibition of Microvesicle and Exosome Release in Prostate Cancer

Therapeutic Solutions International Develops Adjuvant Technology to Enhance Prostate Cancer Suppressing Properties of NanoPSA

Therapeutic Solutions International Develops Glucoraphanin + NanoStilbene Encapsulated product for reduction of Prostate Specific Antigen (PSA)

Therapeutic Solutions International Obtains Exclusive License for Patented Clinical Stage Adult Stem Cell for Treatment of Military and Sports Brain Injuries

Therapeutic Solutions International Continues to Refine NanoStilbene™ Formulation

Therapeutic Solutions International Continues to Expand Chronic Traumatic Encephalopathy Intellectual Property Portfolio

NanoStilbene Enhances Anticancer Immunity in Cancer Patients through Modulation of Inflammatory Mediators

Therapeutic Solutions International Continues to Expand Chronic Traumatic Encephalopathy Intellectual Property Portfolio

Therapeutic Solutions International Signs Agreement for Licensing JadiCell’s Universal Donor Adult Stem Cell Product for Chronic Traumatic Encephalopathy and Traumatic Brain Injury

Therapeutic Solutions International Expands Chronic Traumatic Encephalopathy Intellectual Property Portfolio

Therapeutic Solutions International Announces CTE Optimized NeuroStilbene Formulation

Therapeutic Solutions International Files Patent on Clinical Data Demonstrating Reduction of Inflammatory Cytokines Using NanoStilbene™

Therapeutic Solutions International Collaborates with Internationally Renowned Neurologist and NFL Charger Hall of Famer to Develop New Intellectual Property for Treatment of Chronic Traumatic Encephalopathy

Therapeutic Solutions International Completes Phase 1 Clinical Trial in Advanced Cancer Patients for Right to Try Access of its StemVacs Product for American Cancer Patients

Therapeutic Solutions International Recruits NFL Chargers Hall of Famer Wes Chandler to Lead NeuroStilbene for Chronic Traumatic Encephalopathy in Football Players

TSOI Reports Synergistic Enhancement of Ozone Therapy Efficacy in Prostate, Breast and Ovarian Cancer Cells by Pterostilbene

Therapeutic Solutions International Develops Microemulsion Formulation of Alpha Lipoic Acid for Intranasal Delivery

Therapeutic Solutions International Recruits Internationally Recognized Cancer Immunotherapy Pioneer Dr. Francesco Marincola to Accelerate StemVacs and NanoStilbene Clinical Development

Therapeutic Solutions International, Inc., Releases Intranasal Formulation of Pterostilbene for Rapid Access to Blood-Brain Barrier

Therapeutic Solutions International, Inc., Appoints Juergen Winkler, MD, ABIHM to Scientific Advisory Board

Therapeutic Solutions International Announces Clinical Proof of Concept of Nanoparticle Pterostilbene Formulation: NanoStilbene™

Therapeutic Solutions International Releases “IsoStilbene” Injectable Formulation of Pterostilbene Under Granted Patent for Augmentation of Immunotherapy and Targeting of Cancer Stem Cells

Therapeutic Solutions International Announces the Appointment of James Veltmeyer, MD as Chief Medical Officer

Therapeutic Solutions International Expands Adoptive Immunotherapy Portfolio by Incorporation of “Universal Cancer Antigen” into StemVacs Dendritic Cell Platform

Therapeutic Solutions International Announces Licensing of Additional Technologies to Pan American Cancer Treatment Center

Therapeutic Solutions International to Provide Patients Access to StemVacs Cancer Immunotherapy through Newly Passed Right to Try Law

Therapeutic Solutions International Releases “DermalStilbene” a Topical Formulation of Pterostilbene

Therapeutic Solutions International, Inc., to Initiate Clinical Trial of Patented Cancer Immunotherapy Adjuvant NanoStilbene

Therapeutic Solutions International, Inc., Announces the Appointment of Nassir Azimi, MD, to Science Board

Therapeutic Solutions International Launches Multi-Protocol Cancer Immunotherapy Clinical Trial with Pan Am Cancer Treatment Centers

Therapeutic Solutions International Develops “NanoStilbene” Nanoparticle Formulation of Pterostilbene

Therapeutic Solutions International, Inc. Recruits Top Doctor of San Diego to Scientific Advisory Board

Therapeutic Solutions International, Inc. strengthens the TSOI Scientific Advisory Board with the Appointment of Pablo A. Guzman, MD

Therapeutic Solutions International, Inc. files new patent for the Synergistic Inhibition of Glioma Using Pterostilbene

Therapeutic Solutions International Returns to Fully Reporting Status with SEC

 

For Older Press Releases Visit MarketWired